Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report issued on Friday,Benzinga reports. HC Wainwright currently has a $22.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Morgan Stanley cut their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Stock Down 3.9 %

YMAB stock traded down $0.45 during midday trading on Friday, reaching $11.14. The company had a trading volume of 699,093 shares, compared to its average volume of 242,513. The company has a 50 day moving average of $13.98 and a two-hundred day moving average of $13.09. Y-mAbs Therapeutics has a 1 year low of $5.04 and a 1 year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter in the prior year, the business posted ($0.18) earnings per share. On average, equities analysts anticipate that Y-mAbs Therapeutics will post -0.64 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. This trade represents a 14.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,000 shares of company stock valued at $1,338,100. 22.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its stake in shares of Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD grew its position in Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after acquiring an additional 1,657 shares during the period. Massachusetts Financial Services Co. MA grew its position in Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after acquiring an additional 2,760 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics during the third quarter worth $44,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after acquiring an additional 3,416 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.